{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T01:18:53Z","timestamp":1789003133649,"version":"build-2803163510"},"reference-count":60,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA006927"],"award-info":[{"award-number":["P30 CA006927"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.clgc.2016.08.020","type":"journal-article","created":{"date-parts":[[2016,9,8]],"date-time":"2016-09-08T20:30:51Z","timestamp":1473366651000},"page":"326-335.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["Prostate Cancer Patients With Unmanaged Diabetes or Receiving Insulin Experience Inferior Outcomes and Toxicities After Treatment With Radiation Therapy"],"prefix":"10.1016","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4932-1986","authenticated-orcid":false,"given":"Nicholas G.","family":"Zaorsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talha","family":"Shaikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Ruth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankaj","family":"Sharda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelly B.","family":"Hayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark L.","family":"Sobczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Hallman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc C.","family":"Smaldone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Y.T.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric M.","family":"Horwitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2016.08.020_bib1","first-page":"220","article-title":"Cancer treatment and survivorship statistics, 2012","volume":"62","author":"Siegel","year":"2012","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clgc.2016.08.020_bib2","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.eururo.2013.05.029","article-title":"The mutational landscape of prostate cancer","volume":"64","author":"Barbieri","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2016.08.020_bib3","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.2337\/dc10-0666","article-title":"Diabetes and cancer: a consensus report","volume":"33","author":"Giovannucci","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clgc.2016.08.020_bib4","doi-asserted-by":"crossref","first-page":"e61896","DOI":"10.1371\/journal.pone.0061896","article-title":"Critical role of a survivin\/TGF-beta\/mTORC1 axis in IGF-I-mediated growth of prostate epithelial cells","volume":"8","author":"Song","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.clgc.2016.08.020_bib5","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.urolonc.2011.05.001","article-title":"Insulin-like growth factor pathway: a link between androgen deprivation therapy (ADT), insulin resistance, and disease progression in patients with prostate cancer?","volume":"31","author":"Aggarwal","year":"2013","journal-title":"Urol Oncol"},{"key":"10.1016\/j.clgc.2016.08.020_bib6","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.arr.2014.04.005","article-title":"MicroRNA\u00a0expression altered by diet: can food be medicinal?","volume":"17","author":"Palmer","year":"2014","journal-title":"Ageing Res Rev"},{"key":"10.1016\/j.clgc.2016.08.020_bib7","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1093\/neuonc\/nov096","article-title":"Insulin-mediated signaling promotes proliferation and survival of glioblastoma through Akt activation","volume":"18","author":"Gong","year":"2016","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.clgc.2016.08.020_bib8","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1001\/jama.2008.824","article-title":"Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis","volume":"300","author":"Barone","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.clgc.2016.08.020_bib9","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1038\/bjc.2014.150","article-title":"Does cancer risk increase with HbA1c, independent of diabetes?","volume":"110","author":"de Beer","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clgc.2016.08.020_bib10","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/S1470-2045(08)70235-3","article-title":"Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis","volume":"9","author":"Ma","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2016.08.020_bib11","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.eururo.2012.12.004","article-title":"Metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality","volume":"63","author":"Spratt","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2016.08.020_bib12","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1200\/JCO.2012.46.7043","article-title":"Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes","volume":"31","author":"Margel","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2016.08.020_bib13","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.6004\/jnccn.2013.0174","article-title":"Prostate cancer, version 1.2014","volume":"11","author":"Mohler","year":"2013","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.clgc.2016.08.020_bib14","doi-asserted-by":"crossref","first-page":"5535","DOI":"10.1002\/cncr.27597","volume":"118","author":"Zaorsky","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2016.08.020_bib15","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2337\/dc11-1313","article-title":"Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival","volume":"35","author":"Currie","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clgc.2016.08.020_bib16","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1093\/annonc\/mdr020","article-title":"Thiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patients","volume":"22","author":"He","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2016.08.020_bib17","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2337\/dc08-9025","article-title":"Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"32","author":"Nathan","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clgc.2016.08.020_bib18","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc12-0413","article-title":"Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"35","author":"Inzucchi","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clgc.2016.08.020_bib19","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.ijrobp.2005.07.970","article-title":"Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial","volume":"64","author":"Pollack","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clgc.2016.08.020_bib20","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/nrurol.2013.185","article-title":"Evolution of advanced technologies in prostate cancer radiotherapy","volume":"10","author":"Zaorsky","year":"2013","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.clgc.2016.08.020_bib21","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.radonc.2015.05.011","article-title":"What is the ideal radiotherapy dose to treat prostate cancer? A meta-analysis of biologically equivalent dose escalation","volume":"115","author":"Zaorsky","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clgc.2016.08.020_bib22","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1053\/j.seminoncol.2013.04.011","article-title":"The dilemma of a rising prostate-specific antigen level after local therapy: what are our options?","volume":"40","author":"Zaorsky","year":"2013","journal-title":"Semin Oncol"},{"key":"10.1016\/j.clgc.2016.08.020_bib23","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2217\/fon.13.196","article-title":"A paradigm shift from anatomic to functional and molecular imaging in the detection of recurrent prostate cancer","volume":"10","author":"Zaorsky","year":"2014","journal-title":"Future Oncol"},{"key":"10.1016\/j.clgc.2016.08.020_bib24","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/cncr.23139","article-title":"The phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancer","volume":"112","author":"Abramowitz","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2016.08.020_bib25","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A\u00a0proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J\u00a0Am Stat Assoc"},{"key":"10.1016\/j.clgc.2016.08.020_bib26","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.ctrv.2013.10.006","article-title":"High dose rate brachytherapy boost for prostate cancer: a systematic review","volume":"40","author":"Zaorsky","year":"2014","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clgc.2016.08.020_bib27","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ctrv.2016.06.006","article-title":"Comparison of outcomes and toxicities among radiation therapy treatment options for prostate cancer","volume":"48","author":"Zaorsky","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clgc.2016.08.020_bib28","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1586\/17434440.2013.841347","article-title":"Combining theoretical potential and advanced technology in high-dose rate brachytherapy boost therapy for prostate cancer","volume":"10","author":"Zaorsky","year":"2013","journal-title":"Expert Rev Med Devices"},{"key":"10.1016\/j.clgc.2016.08.020_bib29","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/COC.0000000000000313","article-title":"The missing pieces in reporting of randomized controlled trials of external beam radiation therapy dose escalation for prostate cancer","volume":"39","author":"Zaorsky","year":"2016","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.clgc.2016.08.020_bib30","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/pds.3823","article-title":"No reduced risk of overall, colorectal, lung, breast, and prostate cancer with metformin therapy in diabetic patients: database analyses from Germany and the UK","volume":"24","author":"Kowall","year":"2015","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.clgc.2016.08.020_bib31","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.2337\/dc14-0584","article-title":"Metformin does not affect cancer risk: a cohort study in the U.K. Clinical Practice Research Datalink analyzed like an intention-to-treat trial","volume":"37","author":"Tsilidis","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clgc.2016.08.020_bib32","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1093\/jnci\/djt170","article-title":"Association between metformin use and risk of prostate cancer and its grade","volume":"105","author":"Margel","year":"2013","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clgc.2016.08.020_bib33","doi-asserted-by":"crossref","first-page":"e81594","DOI":"10.1371\/journal.pone.0081594","article-title":"Insulin therapy and risk of prostate cancer: a systematic review and meta-analysis of observational studies","volume":"8","author":"Chen","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.clgc.2016.08.020_bib34","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.clgc.2014.01.001","article-title":"Type 2 diabetes: a protective factor for prostate cancer? An overview of proposed mechanisms","volume":"12","author":"Rastmanesh","year":"2014","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2016.08.020_bib35","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.ijrobp.2007.11.044","article-title":"Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer","volume":"70","author":"Zelefsky","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clgc.2016.08.020_bib36","doi-asserted-by":"crossref","unstructured":"Zaorsky NG, Keith SW, Shaikh T, et\u00a0al. Impact of radiation therapy dose escalation on prostate cancer outcomes and toxicities. Am J Clin Oncol, Published\u00a0online March 24, 2016. http:\/\/dx.doi.org\/10.1097\/COC.0000000000000285.","DOI":"10.1097\/COC.0000000000000285"},{"key":"10.1016\/j.clgc.2016.08.020_bib37","first-page":"329","article-title":"Type 2 diabetes and the risk of mortality among patients with prostate cancer","volume":"25","author":"Bensimon","year":"2014","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.clgc.2016.08.020_bib38","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.2337\/dc06-0997","article-title":"Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin: response to Farooki and Schneider","volume":"29","author":"Bowker","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clgc.2016.08.020_bib39","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1158\/1055-9965.EPI-14-0056","article-title":"The use of metformin in patients with prostate cancer and the risk of death","volume":"23","author":"Bensimon","year":"2014","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.clgc.2016.08.020_bib40","doi-asserted-by":"crossref","first-page":"254","DOI":"10.5114\/jcb.2014.45757","article-title":"Metformin is not associated with improved biochemical free survival or cause-specific survival in men with prostate cancer treated with permanent interstitial brachytherapy","volume":"6","author":"Taira","year":"2014","journal-title":"J\u00a0Contemp Brachytherapy"},{"key":"10.1016\/j.clgc.2016.08.020_bib41","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1002\/cncr.29472","article-title":"Impact of obesity on outcomes after definitive dose-escalated intensity-modulated radiotherapy for localized prostate cancer","volume":"121","author":"Wang","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2016.08.020_bib42","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.eururo.2012.11.013","article-title":"Obesity and prostate cancer: weighing the evidence","volume":"63","author":"Allott","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2016.08.020_bib43","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1016\/j.ejca.2010.06.012","article-title":"Metformin: taking away the candy for cancer?","volume":"46","author":"Jalving","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2016.08.020_bib44","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1053\/j.seminoncol.2013.04.006","article-title":"Multimodality therapy for patients with high-risk prostate cancer: current status and future directions","volume":"40","author":"Zaorsky","year":"2013","journal-title":"Semin Oncol"},{"key":"10.1016\/j.clgc.2016.08.020_bib45","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1093\/jnci\/djm231","article-title":"Association of diet-induced hyperinsulinemia with accelerated growth of prostate cancer (LNCaP) xenografts","volume":"99","author":"Venkateswaran","year":"2007","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clgc.2016.08.020_bib46","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/pros.20852","article-title":"Insulin receptor expression by human prostate cancers","volume":"69","author":"Cox","year":"2009","journal-title":"Prostate"},{"key":"10.1016\/j.clgc.2016.08.020_bib47","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.clgc.2015.03.006","article-title":"Hypoxia and prostate cancer aggressiveness: a tale with many endings","volume":"13","author":"Fraga","year":"2015","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2016.08.020_bib48","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/j.urology.2013.01.047","article-title":"Toxicity after external beam radiotherapy for prostate cancer: an analysis of late morbidity in men with diabetes mellitus","volume":"81","author":"Kalakota","year":"2013","journal-title":"Urology"},{"key":"10.1016\/j.clgc.2016.08.020_bib49","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.10548","article-title":"Necroptosis in tumorigenesis, activation of anti-tumor immunity, and cancer therapy","author":"Meng","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.clgc.2016.08.020_bib50","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1097\/01.CCM.0000170106.61978.D8","article-title":"Acute hyperglycemia and the innate immune system: clinical, cellular, and molecular aspects","volume":"33","author":"Turina","year":"2005","journal-title":"Crit Care Med"},{"key":"10.1016\/j.clgc.2016.08.020_bib51","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S1470-2045(03)01191-4","article-title":"Effects of radiation on normal tissue: consequences and mechanisms","volume":"4","author":"Stone","year":"2003","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2016.08.020_bib52","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2217\/fon.14.123","article-title":"Pericytes: a double-edged sword in cancer therapy","volume":"11","author":"Meng","year":"2015","journal-title":"Future Oncol"},{"key":"10.1016\/j.clgc.2016.08.020_bib53","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1016\/j.eururo.2013.04.014","article-title":"Re: Daniel E. Spratt, Chi Zhang, Zachary S. Zumsteg, Xin Pei, Zhigang Zhang, Michael J. Zelefsky. Metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality. Eur Urol 2013;63:709-16","volume":"64","author":"Bensimon","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2016.08.020_bib54","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1016\/j.eururo.2013.04.015","volume":"64","author":"Spratt","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2016.08.020_bib55","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.eururo.2014.09.028","article-title":"The natural history and predictors of outcome following biochemical relapse in the dose escalation era for prostate cancer patients undergoing definitive external beam radiotherapy","volume":"67","author":"Zumsteg","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2016.08.020_bib56","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.ctrv.2013.01.008","article-title":"Systematic review of hypofractionated radiation therapy for prostate cancer","volume":"39","author":"Zaorsky","year":"2013","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clgc.2016.08.020_bib57","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ctrv.2012.10.003","article-title":"Stereotactic body radiation therapy for prostate cancer: is the technology ready to be the standard of care?","volume":"39","author":"Zaorsky","year":"2013","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clgc.2016.08.020_bib58","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1586\/17434440.2015.994606","article-title":"Is robotic arm stereotactic body radiation therapy \u201cvirtual high dose ratebrachytherapy\u201d for prostate cancer? An analysis of comparative effectiveness using published data [corrected]","volume":"12","author":"Zaorsky","year":"2015","journal-title":"Expert Rev Med Devices"},{"key":"10.1016\/j.clgc.2016.08.020_bib59","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1586\/14737140.2013.836303","article-title":"Do theoretical potential and advanced technology justify the use of high-dose rate brachytherapy as monotherapy for prostate cancer?","volume":"14","author":"Zaorsky","year":"2014","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.clgc.2016.08.020_bib60","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1038\/bjc.2015.353","article-title":"New-onset type 2 diabetes, elevated HbA1c, anti-diabetic medications, and risk of pancreatic cancer","volume":"113","author":"Lu","year":"2015","journal-title":"Br J Cancer"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767316302543?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767316302543?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:27:41Z","timestamp":1761564461000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767316302543"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":60,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["S1558767316302543"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2016.08.020","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prostate Cancer Patients With Unmanaged Diabetes or Receiving Insulin Experience Inferior Outcomes and Toxicities After Treatment With Radiation Therapy","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2016.08.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}